8-K

                     SECURITIES AND EXCHANGE COMMISSION


                           Washington, D.C. 20549

                           ---------------------


                                  FORM 8-K


                               CURRENT REPORT

                   PURSUANT TO SECTION 13 OR 15(D) OF THE
                      SECURITIES EXCHANGE ACT OF 1934


       Date of Report (Date of earliest event reported): May 16, 2002


                           ---------------------

                            IMMUNEX CORPORATION

           (Exact name of registrant as specified in its charter)


          Washington                 0-12406                51-0346580
 (State or other Jurisdiction  (Commission File Number)  (IRS Employer
       of Incorporation)                                 Identification Number)


     51 University Street                                            98101
      Seattle, Washington                                          (Zip Code)
(Address of principal executive
           offices)


     Registrant's telephone number, including area code: (206) 587-0430


                                    N/A
       (Former Name or Former Address, if Changed Since Last Report)





Item 5.  Other Events.

         On May 16, 2002, Immunex Corporation held its Annual Meeting of
Shareholders to vote on the proposed merger of AMS Acquisition Inc., a
wholly-owned subsidiary of Amgen Inc., into Immunex Corporation pursuant to
the Amended and Restated Agreement and Plan of Merger, dated December 16,
2001, by and among Amgen Inc., AMS Acquisition Inc. and Immunex
Corporation. At the meeting, a majority of the outstanding shares of
Immunex common stock entitled to vote were cast in favor of the merger
proposal. A copy of the press release, dated May 16, 2002, announcing the
results of the vote on the merger proposal is attached as exhibit 99.1 to
this Report and is incorporated herein by reference.

Item 7(c). Exhibits.

         See Exhibit Index.


                                 SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the Registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.

                                      IMMUNEX CORPORATION


                                      /s/ Barry G. Pea
                                      -------------------------------
Date:    May 16, 2002                 Name:   Barry G. Pea
                                      Title:  Executive Vice President,
                                              General Counsel and Secretary



                               EXHIBIT INDEX

Exhibit
Number       Document Description

  99.1       Press release announcing shareholder approval of merger proposal.

EX-99

                                                                  Exhibit 99.1

FOR IMMEDIATE RELEASE               CONTACT: Robin Shapiro (media)
May 16, 2002                                 206.389.4040

                                             Mark Leahy (investors)
                                             206.389.4363


                        IMMUNEX SHAREHOLDERS APPROVE
                      PROPOSED MERGER WITH AMGEN INC.

SEATTLE -- Immunex Corporation (Nasdaq: IMNX) announced today that its
shareholders have voted to approve the merger agreement between Immunex and
Amgen Inc. [NASDAQ: AMGN], the largest biotechnology company in the world.
The closing of the merger remains subject to the approval of the Federal
Trade Commission and other customary closing conditions.

An overwhelming majority of the outstanding shares of Immunex common stock,
were cast in favor of the proposed merger. As is customary, a certification
of the votes will be conducted and is expected to be complete next week.

Stockholders of Amgen earlier today approved the issuance of shares of
Amgen common stock required to complete the merger.

"We are very pleased with today's shareholder approval of our merger with
Amgen," said Ed Fritzky, Immunex chairman and chief executive officer. "The
strategic vision of the combined companies will expand future patient
benefits by harnessing the significant resources, talents and assets of our
companies."

The company expects the merger to be completed in the second half of 2002
and could be completed as early as June 2002, although the exact timing
cannot be predicted with certainty.

Immunex Corporation is a leading biopharmaceutical company dedicated to
improving lives through immune system science innovations.

Note: Except for the historical information contained herein, this news
release contains forward-looking statements that involve substantial risks
and uncertainties. Among the factors that could cause actual results or
timelines to differ materially are risks associated with research and
clinical development, regulatory approvals, our supply capabilities and
reliance on third-party manufacturers, product commercialization,
competition, litigation and other risk factors listed from time to time in
reports filed by Immunex with the Securities and Exchange Commission,
including but not limited to risks described under the caption "Important
Factors That May Affect Our Business, Our Results of Operation and Our
Stock Price" within our most recently filed Form 10-Q. The forward-looking
statements contained in this news release represent our judgment as of the
date of this release. Immunex undertakes no obligation to publicly update
any forward-looking statements. An electronic version of this news
release-as well as additional information about Immunex of interest to
investors, customer, future employees and patients-is available on the
Immunex home page at www.immunex.com.

                                   # # #